Isthmus Partners LLC Raises Position in Lantheus Holdings, Inc. $LNTH

Isthmus Partners LLC increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 60.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,768 shares of the medical equipment provider’s stock after buying an additional 14,628 shares during the quarter. Isthmus Partners LLC owned about 0.06% of Lantheus worth $2,580,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Osterweis Capital Management Inc. purchased a new stake in shares of Lantheus during the 2nd quarter valued at $36,000. Hantz Financial Services Inc. boosted its holdings in Lantheus by 412.5% in the third quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 396 shares during the last quarter. First Horizon Corp purchased a new stake in Lantheus during the third quarter valued at about $26,000. Farther Finance Advisors LLC increased its stake in Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 275 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in Lantheus by 30.3% during the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after acquiring an additional 230 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LNTH has been the topic of several research reports. JonesTrading lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Citizens Jmp increased their price objective on shares of Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a research report on Friday, May 8th. William Blair reissued an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Mizuho lifted their target price on shares of Lantheus from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Lantheus presently has an average rating of “Moderate Buy” and an average price target of $99.71.

Lantheus Stock Down 2.9%

Shares of NASDAQ:LNTH opened at $93.91 on Friday. The firm has a market cap of $6.11 billion, a PE ratio of 22.63 and a beta of -0.08. The company has a fifty day simple moving average of $81.92 and a 200 day simple moving average of $70.39. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $98.27.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. During the same quarter last year, the firm earned $1.53 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.3 EPS for the current fiscal year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.